StockNews.com Initiates Coverage on InVivo Therapeutics (NASDAQ:NVIV)

StockNews.com initiated coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Get Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock. Shares of NASDAQ NVIV opened at $4.89 on Monday. The stock has a market cap of $6.80 million, a PE ratio of -0.64 and […]

Related Keywords

,Morgan Stanley ,Sigma Securities ,Goldman Sachs Group Inc ,Virtu Financial ,Invivo Therapeutics Holdings Corp ,Renaissance Technologies ,Invivo Therapeutics ,Get Rating ,Vivo Therapeutics ,Goldman Sachs Group ,Vivo Therapeutics Holdings Corp ,Neuro Spinal Scaffold ,Nasdaq Nviv ,Enviv ,Medical ,Initiated Coverage ,Stocknews Com ,